Currently, there are 99.94M common shares owned by the public and among those 72.54M shares have been available to trade.
The company’s stock has a 5-day price change of 3.55% and -66.00% over the past three months. SLRN shares are trading -35.03% year to date (YTD), with the 12-month market performance down to -74.18% lower. It has a 12-month low price of $1.86 and touched a high of $8.89 over the same period. SLRN has an average intraday trading volume of 1.05 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 2.67%, -31.47%, and -54.60% respectively.
Institutional ownership of Acelyrin Inc (NASDAQ: SLRN) shares accounts for 69.55% of the company’s 99.94M shares outstanding.
It has a market capitalization of $205.43M and a beta (3y monthly) value of 1.85. The earnings-per-share (ttm) stands at -$2.68. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.93% over the week and 7.33% over the month.
Earnings per share for the fiscal year are expected to increase by 53.73%, and 13.43% over the next financial year.
Looking at the support for the SLRN, a number of firms have released research notes about the stock. H.C. Wainwright stated their Neutral rating for the stock in a research note on August 14, 2024, with the firm’s price target at $18-$6. Wells Fargo coverage for the Acelyrin Inc (SLRN) stock in a research note released on July 08, 2024 offered a Overweight rating with a price target of $13. Wells Fargo was of a view on December 13, 2023 that the stock is Equal Weight, while Citigroup gave the stock Neutral rating on December 08, 2023, issuing a price target of $8. Morgan Stanley on their part issued Equal-Weight rating on September 13, 2023.
